RecruitingPhase 3NCT06281977

Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm

Sponsor

Ottawa Heart Institute Research Corporation

Enrollment

192 participants

Start Date

May 8, 2024

Study Type

INTERVENTIONAL

Conditions

Ventricular Tachycardia Ventricular arrhythmias Ventricular Fibrillation Recurrent Ventricular Tachycardia

Summary

The objective of this study is to determine if there is a meaningful benefit to using the sedative medication dexmedetomidine in the acute treatment of patients with recurrent ventricular arrhythmias, known as electrical storm. This will be a multi-centre, double-blinded, placebo-controlled, randomized trial. Patients with electrical storm will be randomized to receive 48 to 72 hours of dexmedetomidine or placebo as part of their initial treatment in an intensive care unit.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Dexmedetomidine and a drug called Normal saline for people with recurrent ventricular tachycardia, ventricular fibrillation, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.